{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:52Z","timestamp":1784764852990,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.maturitas.2026.109036","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:11:49Z","timestamp":1782573109000},"page":"109036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A practical approach to breast cancer risk assessment and management of women at elevated risk"],"prefix":"10.1016","volume":"211","author":[{"given":"Elizabeth","family":"Etkin-Kramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly J.","family":"Pederson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10286","key":"10.1016\/j.maturitas.2026.109036_bb0005","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.maturitas.2026.109036_bb0015","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1245\/s10434-012-2257-y","article-title":"Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers","volume":"19","author":"Cuzick","year":"2012","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.maturitas.2026.109036_bb0020","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3122\/jabfm.2020.06.190461","article-title":"BRCA-related cancer genetic counseling is indicated in many women seeking primary care","volume":"33","author":"Parente","year":"2020","journal-title":"J. Am. Board Fam. Med."},{"issue":"5","key":"10.1016\/j.maturitas.2026.109036_bb0025","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/AOG.0000000000002916","article-title":"Hereditary cancer risk assessment and genetic testing in the community-practice setting","volume":"132","author":"DeFrancesco","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.maturitas.2026.109036_bb0035","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/jama.2019.11885","article-title":"Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement","volume":"322","author":"US Preventive Services Task Force","year":"2019","journal-title":"JAMA"},{"issue":"33","key":"10.1016\/j.maturitas.2026.109036_bb0040","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.19.01472","article-title":"Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update","volume":"37","author":"Visvanathan","year":"2019","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.maturitas.2026.109036_bb0050","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jacr.2023.04.002","article-title":"Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR","volume":"20","author":"Monticciolo","year":"2023","journal-title":"J. Am. Coll. Radiol."},{"issue":"20","key":"10.1016\/j.maturitas.2026.109036_bb0055","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.maturitas.2026.109036_bb0060","first-page":"379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","volume":"107","author":"Manchanda","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.maturitas.2026.109036_bb0065","first-page":"111","article-title":"Cancer statistics for African American and Black people, 2025","volume":"75","author":"Saka","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.maturitas.2026.109036_bb0070","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/jnci\/djag002","article-title":"Current state of mammography-based artificial intelligence for future breast cancer risk prediction: a systematic review","volume":"118","author":"Lowry","year":"2026","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2026.109036_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djag083","article-title":"Performance of clinical breast cancer risk prediction models versus a mammography-based artificial intelligence risk model","author":"Kaul","year":"2026","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.maturitas.2026.109036_bb0080","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B","article-title":"Family history and the risk of breast cancer: a systematic review and meta-analysis","volume":"71","author":"Pharoah","year":"1997","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.maturitas.2026.109036_bb0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO\u2013Society of Surgical Oncology guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.maturitas.2026.109036_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJMsr1407164","article-title":"Atypical hyperplasia of the breast \u2014 risk assessment and management options","volume":"372","author":"Hartmann","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"33","key":"10.1016\/j.maturitas.2026.109036_bb0095","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2015.61.4743","article-title":"Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk","volume":"33","author":"King","year":"2015","journal-title":"JCO"},{"issue":"19","key":"10.1016\/j.maturitas.2026.109036_bb0100","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/jnci\/dji290","article-title":"Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma","volume":"97","author":"Travis","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.maturitas.2026.109036_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju255","article-title":"Prevalence of mammographically dense breasts in the United States","volume":"106","author":"Sprague","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.maturitas.2026.109036_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002335","article-title":"Mammographic density and ageing: a collaborative pooled analysis of cross-sectional data from 22 countries worldwide","volume":"14","author":"Burton","year":"2017","journal-title":"PLoS Med."},{"issue":"11","key":"10.1016\/j.maturitas.2026.109036_bb0115","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1158\/1055-9965.EPI-15-0330","article-title":"The effect of change in body mass index on volumetric measures of mammographic density","volume":"24","author":"Hart","year":"2015","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"3","key":"10.1016\/j.maturitas.2026.109036_bb0120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10549-020-05744-w","article-title":"Hormone replacement therapy and mammographic density: a systematic literature review","volume":"182","author":"Azam","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2026.109036_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111837","article-title":"Extremely dense breasts: a comprehensive review of increased cancer risk and supplementary screening methods","volume":"182","author":"Nissan","year":"2025","journal-title":"Eur. J. Radiol."},{"issue":"2","key":"10.1016\/j.maturitas.2026.109036_bb0130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/aje\/kwae245","article-title":"Breast density and risk of breast cancer: masking and detection bias","volume":"194","author":"Lange","year":"2025","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.maturitas.2026.109036_bb0135","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/ijc.34316","article-title":"Breast density and risk of breast cancer","volume":"152","author":"Lynge","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"13","key":"10.1016\/j.maturitas.2026.109036_bb0140","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.maturitas.2026.109036_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232800","article-title":"Risk of second primary breast cancer among cancer survivors: implications for prevention and screening practice","volume":"15","author":"Cheng","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.maturitas.2026.109036_bb0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.breast.2023.01.003","article-title":"Polygenic risk scores and breast cancer risk prediction","volume":"67","author":"Roberts","year":"2023","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.maturitas.2026.109036_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101128","article-title":"Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors","volume":"26","author":"Mabey","year":"2024","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.maturitas.2026.109036_bb0160","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002158","article-title":"Practice bulletin number 179: breast cancer risk assessment and screening in average-risk women","volume":"130","year":"2017","journal-title":"Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.maturitas.2026.109036_bb0165","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jacr.2017.06.001","article-title":"Breast cancer screening for average-risk women: recommendations from the ACR Commission on Breast Imaging","volume":"14","author":"Monticciolo","year":"2017","journal-title":"J. Am. Coll. Radiol."},{"issue":"22","key":"10.1016\/j.maturitas.2026.109036_bb0170","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1001\/jama.2024.5534","article-title":"Screening for breast cancer: US Preventive Services Task Force recommendation statement","volume":"331","author":"US Preventive Services Task Force","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.maturitas.2026.109036_bb0175","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jmri.26654","article-title":"Contrast-enhanced MRI for breast cancer screening","volume":"50","author":"Mann","year":"2019","journal-title":"J. Magn. Reson. Imaging"},{"issue":"23","key":"10.1016\/j.maturitas.2026.109036_bb0180","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.maturitas.2026.109036_bb0185","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"10218","key":"10.1016\/j.maturitas.2026.109036_bb0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","article-title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial","volume":"395","author":"Cuzick","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.maturitas.2026.109036_bb0195","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.maturitas.2026.109036_bb0200","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"JCO"},{"issue":"13","key":"10.1016\/j.maturitas.2026.109036_bb0205","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1158\/1078-0432.CCR-20-4213","article-title":"Effect modifiers of low-dose tamoxifen in a randomized trial in breast noninvasive disease","volume":"27","author":"DeCensi","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.maturitas.2026.109036_bb0210","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/1940-6207.CAPR-24-0324","article-title":"Improved uptake and adherence to risk-reducing medication with the use of low-dose tamoxifen in patients at high risk for breast cancer","volume":"17","author":"Cornell","year":"2024","journal-title":"Cancer Prev. Res."},{"issue":"4","key":"10.1016\/j.maturitas.2026.109036_bb0215","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-20-3609","article-title":"A randomized phase IIb study of low-dose tamoxifen in chest-irradiated cancer survivors at risk for breast cancer","volume":"27","author":"Bhatia","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.maturitas.2026.109036_bb0220","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.breast.2015.07.013","article-title":"Impact of preventive therapy on the risk of breast cancer among women with benign breast disease","volume":"24","author":"Cuzick","year":"2015","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.maturitas.2026.109036_bb0225","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/tbj.13969","article-title":"Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer","volume":"26","author":"Wood","year":"2020","journal-title":"Breast J."},{"issue":"12","key":"10.1016\/j.maturitas.2026.109036_bb0230","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"20","key":"10.1016\/j.maturitas.2026.109036_bb0235","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1001\/jama.2024.6542","article-title":"The Women\u2019s Health Initiative randomized trials and clinical practice: a review","volume":"331","author":"Manson","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.maturitas.2026.109036_bb0240","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1940-6207.CAPR-19-0315","article-title":"Effect of bazedoxifene and conjugated estrogen (Duavee) on breast cancer risk biomarkers in high-risk women: a pilot study","volume":"12","author":"Fabian","year":"2019","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"2","key":"10.1016\/j.maturitas.2026.109036_bb0245","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1245\/s10434-024-16484-2","article-title":"Indications, outcomes, and risks","volume":"32","author":"Mastectomy","year":"2025","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.maturitas.2026.109036_bb0255","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/01.AOG.0000445584.44898.7d","article-title":"ACOG Committee Opinion no. 593: management of women with dense breasts diagnosed by mammography","volume":"123","author":"Committee on Gynecologic Practice","year":"2014","journal-title":"Obstet. Gynecol."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226002136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226002136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:03:07Z","timestamp":1784761387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"alternative-id":["S0378512226002136"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.109036","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A practical approach to breast cancer risk assessment and management of women at elevated risk","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.109036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109036"}}